Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03134339
Other study ID # 1609018390
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date January 5, 2017
Est. completion date January 29, 2018

Study information

Verified date October 2018
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The dose-effect curve to estimate a threshold delivery rate for reinforcement. The project addresses the FDA Center for Tobacco Products (CTP) interest #1: Nicotine dependence threshold among youth and adults and impact of nicotine reduction on tobacco product use behavior (e.g., topography, compensation, switching, multiple use, initiation, cessation and relapse). IV nicotine, in contrast to ECs, can deliver precise, reproducible dosing, which is necessary for accurately assessing dose-response and threshold effects. The estimated threshold for reinforcement will establish a benchmark for evaluating the addictive potential of ECs and other inhaled nicotine products.


Description:

A placebo-controlled study that will recruit male and female nicotine dependent smokers/EC users (n=18) to complete four separate experimental sessions. Each session will include one randomly assigned infusion that will be either saline or a single dose of nicotine (1 mg per 70 kg body weight) delivered at three different infusion rates, rapid, moderate or slow (0.24, 0.048 or 0.024 mcg per kg body weight per second). A total infusion duration of 10 min will be maintained during each session by adding saline infusions of variable duration after nicotine delivery. This will be achieved by two separate infusion pumps, one for saline and one for nicotine. For example, the rapid 0.24 mcg/kg/s condition will include a 1 min infusion of nicotine followed by a 9 min infusion of saline. The subjects will be blinded to the infusion pump procedures. The rapid delivery rate, which we have used in our prior studies, induces positive subjective drug effects and suppresses symptoms of nicotine withdrawal. The moderate delivery rate,0.048 mcg/kg/s, approximates the rate of nicotine intake encountered while smoking a typical cigarette over 5 min (4). The slowest nicotine delivery rate, 0.024mcg/kg/s, was chosen to approximate the rate of nicotine intake encountered while using a newer EC (5).


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date January 29, 2018
Est. primary completion date January 29, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria:

1. Female and male smokers that smoke = 5 cigarettes per day for the past year

2. aged 18 to 30 years

3. urine cotinine levels > 100 ng/mL consistent with nicotine intake of an active smoker (23)

4. not seeking treatment at the time of the study for nicotine dependence

5. in good health as verified by medical history, screening examination, and screening laboratory tests

6. for women, not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods.

Exclusion Criteria:

1. history of major medical or psychiatric disorders that the physician investigator deems as contraindicated for the subject to be in the study

2. regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics)

3. current alcohol or substance dependence for any other recreational or prescription drugs other than nicotine

4. urine drug screening indicating recent illicit drugs use (with the exception of marijuana).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nicotine saline 0.00mcg/kg/s
saline 0.00mcg/kg/s
Nicotine 0.24 mcg/kg/s
nicotine 0.24 mcg/kg/s
Nicotine 0.048 mcg/kg/s
nicotine 0.048 mcg/kg/s
Nicotine 0.024 mcg/kg/s
nicotine 0.024 mcg/kg/s

Locations

Country Name City State
United States VA Hospital West Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Peak Change on items of the Drug Effects Questionnaire (DEQ) The peak change in the intensity of subjective effects as measured by the DEQ up to 60 minutes post infusion
See also
  Status Clinical Trial Phase
Terminated NCT03576768 - QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt N/A
Completed NCT04124432 - Behavioral Pharmacology of Cannabis and Nicotine Phase 1
Enrolling by invitation NCT04038515 - Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes Phase 2
Completed NCT01223404 - Nicotinic Modulation of the Default Network N/A
Recruiting NCT05864586 - Developing E-liquid Product Standards (Sweet Spot Study) N/A
Completed NCT01227343 - Nicotine and Brain Imaging Research Study
Completed NCT05317195 - Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers N/A
Withdrawn NCT03010995 - The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study Phase 1
Active, not recruiting NCT04189146 - Inner Engineering Yoga Program on Short and Long Term Health Effects (ISHA-Impact): A Longitudinal Study N/A
Completed NCT05487456 - Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence N/A
Completed NCT03102931 - Switching to Low Oxidant Content Cigarettes in Adult Smokers N/A
Recruiting NCT06346353 - Substance Consumption, Personality, and Cognitive Functioning of Chess Players
Completed NCT05383508 - Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes N/A